Abstract Details

Title Cross-Sectional and Longitudinal Neuropsychological Assessment in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis

Topic Behavioral Neurology

Presentation(s) P07 - (-)

Poster/Presentation
Number 166

Objective

Background BACKGROUND: Both Amyotrophic Lateral Sclerosis (ALS) and Primary Lateral Sclerosis (PLS) can present with neuropsychological deficits, particularly involving executive control. Neuropsychological profiles both within- and between group have not been compared longitudinally.

Design/Methods DESIGN/METHODS: Neuropsychological functioning was assessed with the Philadelphia Brief Assessment of Cognition (PBAC) that measures executive, language, visuospatial, memory and behavior/comportment deficits associated with dementia. 47 definite/ probable ALS and 15 PLS patients were tested; longitudinal data over 11 months (range 9-13 months) was available for 15 ALS and 5 PLS patients. PBAC percent correct scores were analyzed. There were no differences for age (M +SD=61.70+11.37), education (M+SD=13.63+2.22), MMSE (M+SD=26.82+3.38), or ALS-FRS scores (M+SD=30.63+10.56).

Results RESULTS: Baseline cross-sectional assessment revealed no between-group differences for total PBAC performance (M ALS=76.53 +8.20; M PLS=73.00 +14.44) or on any PBAC subscale. At baseline paired t-tests for ALS patients found lower scores on the PBAC-executive versus all other subscales (p< 0.001, all analyses) and lower PBAC-memory performance compared to language, visuospatial, and behavior/ comportment subscales (p< 0.001, analyses). In PLS baseline assessment found equal impairment on PBAC executive and memory subscales with worse executive/ memory performance compared to other neuropsychological/ behavioral domains (p< 0.001, all analyses). Within-group longitudinal analyses found no decline for total PBAC or PBAC subscale performance in either group.

Conclusions CONCLUSIONS: Baseline neuropsychological assessment found equal levels of executive and memory impairment in ALS and PLS. Longitudinally PBAC scores were stable in both groups. Further research to examine for longitudinal decline over longer time periods is needed.

Authors/Disclosures
David J. Libon, PhD (Rowan Univerity) PRESENTER	No disclosure on file
Terry D. Heiman-Patterson, MD (Temple University Lewis Katz School of Medicine)	Dr. Heiman-Patterson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MTPA. Dr. Heiman-Patterson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Dr. Heiman-Patterson has received personal compensation in the range of $0-$499 for serving as a Consultant for novartis. Dr. Heiman-Patterson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for biogen. The institution of Dr. Heiman-Patterson has received research support from MTPA. The institution of Dr. Heiman-Patterson has received research support from State of Pennsylvania . The institution of Dr. Heiman-Patterson has received research support from ALS Association. The institution of Dr. Heiman-Patterson has received research support from ALS United. The institution of Dr. Heiman-Patterson has received research support from ALS Hope Foundation.
Carol F. Lippa, MD (Thomas Jefferson University)	Dr. Lippa has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Anahita F. Deboo, MD (Temple University School of Medicine - Neurology)	Dr. Deboo has nothing to disclose.
Krzysztof W. Selmaj (University of Warmia and Mazury)	Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astra. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.

��ɫ��

��ɫ��